Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.

Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, Hamajima N, Hashimoto S.

Clin Chim Acta. 2013 Sep 23;424:99-103. doi: 10.1016/j.cca.2013.05.021. Epub 2013 May 30.

PMID:
23727030
2.

Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L.

PLoS One. 2011;6(8):e23937. doi: 10.1371/journal.pone.0023937. Epub 2011 Aug 23.

3.

Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.

Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO.

PLoS One. 2016 Apr 14;11(4):e0153497. doi: 10.1371/journal.pone.0153497. eCollection 2016.

4.

Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.

Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R, Hashimoto S.

Clin Chim Acta. 2015 Jun 15;446:267-71. doi: 10.1016/j.cca.2015.05.002. Epub 2015 May 7.

PMID:
25958847
5.

Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.

Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, Xu ZJ, Chen YW, Fan JG.

World J Gastroenterol. 2016 Nov 28;22(44):9844-9852.

6.

Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.

Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S.

Gut. 2015 May;64(5):800-12. doi: 10.1136/gutjnl-2014-306996. Epub 2014 Jun 27.

7.

Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.

Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, Pogribny IP.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):52-9. doi: 10.1016/j.taap.2012.04.018. Epub 2012 Apr 24.

8.

Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.

Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K.

Liver Int. 2014 Aug;34(7):e302-7. doi: 10.1111/liv.12429. Epub 2014 Jan 7.

PMID:
24313922
9.

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.

Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM.

J Hepatol. 2013 Jan;58(1):119-25. doi: 10.1016/j.jhep.2012.08.008. Epub 2012 Aug 15.

PMID:
22902550
10.

Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease.

Razavizade M, Jamali R, Arj A, Talari H.

Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):513-20.

11.

Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.

Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V, Younossi ZM.

Aliment Pharmacol Ther. 2010 Aug;32(3):487-97. doi: 10.1111/j.1365-2036.2010.04366.x. Epub 2010 May 22.

12.

Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.

Liu PJ, Ma F, Lou HP, Zhu YN, Chen Y.

Climacteric. 2014 Dec;17(6):692-9. doi: 10.3109/13697137.2014.926323. Epub 2014 Aug 7.

PMID:
24884478
13.

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.

Ding J, Li M, Wan X, Jin X, Chen S, Yu C, Li Y.

Sci Rep. 2015 Sep 2;5:13729. doi: 10.1038/srep13729.

14.

Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease.

Zhang Y, Cheng X, Lu Z, Wang J, Chen H, Fan W, Gao X, Lu D.

Diabetes Res Clin Pract. 2013 Mar;99(3):327-34. doi: 10.1016/j.diabres.2012.11.025. Epub 2012 Dec 31.

PMID:
23287814
15.

Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome.

Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J.

World J Gastroenterol. 2012 Apr 7;18(13):1508-16. doi: 10.3748/wjg.v18.i13.1508.

16.

Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.

Soronen J, Yki-Järvinen H, Zhou Y, Sädevirta S, Sarin AP, Leivonen M, Sevastianova K, Perttilä J, Laurila PP, Sigruener A, Schmitz G, Olkkonen VM.

Physiol Rep. 2016 Jan;4(1). pii: e12661. doi: 10.14814/phy2.12661.

17.

Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians--(CURES - 81).

Gokulakrishnan K, Anjana RM, Indulekha K, Anuradha S, Mohan V.

Indian J Med Res. 2010 Sep;132:271-7.

18.

Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

Goulart AC, Oliveira IR, Alencar AP, Santos MS, Santos IS, Martines BM, Meireles DP, Martines JA, Misciagna G, Benseñor IM, Lotufo PA.

Sao Paulo Med J. 2015 Mar-Apr;133(2):115-24. doi: 10.1590/1516-3180.2014.9150812. Epub 2015 Apr 1.

19.

Circulating microRNAs in patients with non-alcoholic fatty liver disease.

Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M.

World J Hepatol. 2014 Aug 27;6(8):613-20. doi: 10.4254/wjh.v6.i8.613.

20.

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ.

Cell Metab. 2012 May 2;15(5):665-74. doi: 10.1016/j.cmet.2012.04.004.

Supplemental Content

Support Center